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Cohort: Does the ADDITION Validation Add Up?We read with interest the article published in Value in Health,
assessing the performance of the United Kingdom Prospective
Diabetes Study (UKPDS) outcomes model against observed events
in the Anglo-Danish-Dutch Study of Intensive Treatment In
PeOple With screeN Detected Diabetes in Primary Care (ADDI-
TION-Europe) trial cohort [1]. Such studies should be welcomed
because they are very valuable in assessing the external validity
of models such as the UKPDS outcomes model.
There were however some aspects of the analysis that were
not completely clear and others that are potentially misleading:1. The article does not make clear how risk factors such as
cholesterol and systolic blood pressure were dealt with during
the extrapolation period. If the user does not input such
values, for example, holding them constant, the model default
is to predict a future trajectory reﬂecting natural history
rather than therapeutic control, and this will considerably
increase the predicted risk of events.2. Normally, the literature comparing actual and predicted
events reports conﬁdence intervals around the actual event
rates to assess whether the predicted rates fall within the
conﬁdence intervals of the actual data. The uncertainty in the
data used in this exercise is clearly crucial because patients
are divided into three countries and two treatment groups to
make these comparisons, although the trial article [2] reported
no signiﬁcant differences between countries and nonsigniﬁ-
cant differences between treatment arms in cardiovascular
events and deaths. It is therefore surprising to see that only
point estimates were reported for the actual rates in this
article.
From our approximate back-calculation of actual event rate
numbers and rates, and conﬁdence intervals around these, we
ﬁnd it extremely hard to believe that the predicted rates are
signiﬁcantly higher than the actual rates in all comparisons,
as claimed. For instance, in the case of the United Kingdom,
the reported actual stroke rate in the routine care group is
0.0180, which is probably nine events. We predict a rate of
0.0208, or 10 events. How can a t test comparing mean
predicted and actual rates for that group indicate a signiﬁcant
difference with a reported P value of less than 0.001? Similarly
for the other stroke comparisons in Table 2. Reporting of the
actual numbers and associated conﬁdence intervals around
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Related to this point, it is not clear how the reported uncer-
tainty around the predicted rate was calculated: is it based on
bootstrapped equation sets provided with the UKPDS out-
comes model, which should capture parameter uncertainty in
the model equations, or is it in fact based on patient varia-
bility in the model, or even Monte-Carlo error?3. As Tao et al. [1] note, the ADDITION trial article [2] reported
separately a cardiovascular death rate (1.6% vs. 1.5%) and a
nonfatal myocardial infarction (MI) rate (2.3% vs. 1.7%). The
validation article however reports just one MI rate (3.0% vs.
1.7%). Because the validation is conducted in a subset of the
trial article, and is not restricted only to ﬁrst events, it is not
completely clear how the trial data have been reclassiﬁed, but
it appears that only nonfatal MIs and nonfatal strokes have
been included in the analysis. If this is the case, the compar-
ison by Tao et al. [1] with the predictions of the UKPDS
outcomes model is fundamentally ﬂawed because the MIs
and strokes predicted by the model include fatal and nonfatal
events; this is made abundantly clear in the model documen-
tation and accompanying publication [3]. For the record,
approximately 60% of all MIs in the UKPDS were fatal, and
34% of strokes, so it is hardly surprising that a comparison of
observed (nonfatal) MIs and strokes in ADDITION-Europe with
predicted (nonfatal and fatal) MIs and strokes using the
UKPDS outcomes model might conclude that the model was
overpredicting these events.
As stated earlier, assessments of the external validity of
disease models can be of great value but need to be carefully
conducted and reported in accordance with good practice
guidelines [4]. Version 2 of the UKPDS outcomes model
was published in 2013, and approved software should be
available by late 2014 [5]. Version 1, used by Tao et al. [1],
may overestimate some categories of cardiovascular disease
risk in some populations, although other published studies
have not invariably found this: see, for example, comparisons
with large Italian and American cohorts [6,7]. Meanwhile,
readers should handle the comparison by Tao et al. [1]
with caution: It does not, to our mind, offer any reliable
evidence of signiﬁcant differences between actual outcomes
in the ADDITION-Europe study and UKPDS outcomes model
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In JVAL 17/7, the abstract entitled on page A806, entitled “Cost-Effectiveness of Maternal Immunisation for Pertussis in New Zealand” by J.E. Poirrier,
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